Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 1/20 | 0.37 |
| ▸ | APLNR | P35414 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 2/20 | 0.32 |
| ▸ | TDO2 | P48775 | 2/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16843269 | 0.84 | AOC3 (0.37) | AOC3APLNRCA2IDO1TDO2 | |
| SCHEMBL5223462 | 0.84 | AOC3 (0.37) | AOC3APLNRCA2IDO1TDO2 | |
| SCHEMBL16843372 | 0.83 | AOC3 (0.41) | AOC3IDO1TDO2SLC6A4SLC6A2 | |
| SCHEMBL28449967 | 0.82 | AOC3 (0.43) | AOC3APLNRCA2IDO1TDO2 | |
| SCHEMBL15948268 | 0.81 | AOC3 (0.39) | AOC3APLNRCA2IDO1TDO2 | |
| SCHEMBL27933551 | 0.81 | CA2 (0.36) | AOC3CA2IDO1TDO2SLC6A4 | |
| SCHEMBL12385546 | 0.80 | CA2 (0.30) | CA2 | |
| SCHEMBL20854970 | 0.80 | AOC3 (0.35) | AOC3APLNRCA2SLC6A2 | |
| SCHEMBL20640965 | 0.80 | AOC3 (0.35) | AOC3APLNRCA2SLC6A4SLC6A2 | |
| SCHEMBL15957314 | 0.80 | AOC3 (0.35) | AOC3CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9926269-B2 | Beta-lactam cholesterol absorption inhibitors | RUDJER BOSKOVIC INSTITUTE (HR) | 2018-03-27 | — | — | US | disclosed |
| US-9926269-B2 | Beta-lactam cholesterol absorption inhibitors | RUDJER BOSKOVIC INSTITUTE (HR) | 2018-03-27 | — | — | US | disclosed |
| US-20160355473-A1 | BETA-LACTAM CHOLESTEROL ABSORPTION INHIBITORS | RUDJER BOSKOVIC INSTITUTE (HR) | 2016-12-08 | — | — | US | disclosed |
| US-20160355473-A1 | BETA-LACTAM CHOLESTEROL ABSORPTION INHIBITORS | RUDJER BOSKOVIC INSTITUTE (HR) | 2016-12-08 | — | — | US | disclosed |
| US-20160355473-A1 | BETA-LACTAM CHOLESTEROL ABSORPTION INHIBITORS | RUDJER BOSKOVIC INSTITUTE (HR) | 2016-12-08 | — | — | US | disclosed |
| US-20100125059-A1 | 1-BIARYLAZETIDINONE DERIVATIVE | TEIJIN PHARMA LIMITED (JP) | 2010-05-20 | — | — | US | disclosed |
| US-20100125059-A1 | 1-BIARYLAZETIDINONE DERIVATIVE | TEIJIN PHARMA LIMITED (JP) | 2010-05-20 | — | — | US | disclosed |
| EP-2133347-A1 | 1-BIARYLAZETIDINONE DERIVATIVES | Teijin Pharma Limited (JP) | 2009-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160355473-A1 | BETA-LACTAM CHOLESTEROL ABSORPTION INHIBITORS | PCSK9, CETP, NPC1L1 | AOC3 4295/4885APLNR 3209/4885CA2 3476/4885 |
| US-20100125059-A1 | 1-BIARYLAZETIDINONE DERIVATIVE | PCSK9, CYP46A1, HMGCR | AOC3 3723/4885APLNR 3555/4885CA2 2690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.